Empagliflozin treatment prevents liver fibrosis as well as hepatic steatosis [60], and metformin reduces protein levels of the cancer marker CD133 through the AMPK-CCAAT/enhancer-binding protein beta (CEBPβ) signaling pathway [61]. The gene discussed is CEBPB; the disease is fatty liver disease.